Ivermectin Stada

Ivermectin, the active ingredient in Ivermectin Stada, is an anthelmintic (macrocyclic lactone) presented as an oral formulation for oral use. It treats a range of parasitic infections in humans, including strongyloidiasis, onchocerciasis, scabies, lice infestations and other helminth infections.

GNH USA supplies Ivermectin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an anthelmintic that targets parasitic infections.

Strongyloidiasis: eliminates the intestinal worm Strongyloides stercoralis. Onchocerciasis (river blindness): reduces microfilarial load and prevents disease progression. Scabies: eradicates Sarcoptes scabiei mites causing crusted and ordinary scabies. Lice infestations: eliminates head and body lice. Other helminth infections: treats various nematode infections such as ascariasis and hookworm.

Ivermectin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhoea - Dizziness - Skin rash

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or other severe skin reactions - Seizures or encephalopathy - Hepatotoxicity

Before prescribing Ivermectin, clinicians should consider several safety aspects.

Assess for contraindications: avoid in patients with known hypersensitivity to ivermectin or other macrocyclic lactones. Evaluate infection severity: use with caution in patients with high parasite burden to reduce risk of severe inflammatory reactions. Consider co‑morbidities: monitor liver function in patients with hepatic impairment. Pregnancy and lactation: use only if the benefit outweighs the risk; consult the prescriber. Drug interactions: review concomitant medications, especially those affecting CYP3A4. Store at ambient temperature: keep below 25°C, retain in the original packaging, and protect from moisture and light.

Ivermectin can interact with several medicines, requiring careful review.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil) may raise exposure. - Co‑administration with other neurotoxic agents (e.g., benzimidazoles) may increase neurotoxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin) may reduce efficacy. - Anticoagulants (e.g., warfarin) may have altered effect. - Anticonvulsants (e.g., carbamazepine) may affect seizure threshold.